About Cellectar Biosciences
Cellectar Biosciences is a company based in Florham Park (United States) founded in 2002 was acquired by Novelos Therapeutics in April 2011.. The company has 11 employees as of December 31, 2024. Cellectar Biosciences operates in a competitive market with competitors including Insulet, Lyra Therapeutics, TriSalus Life Sciences, Credence MedSystems and Foresee Pharmaceuticals, among others.
- Headquarter Florham Park, United States
- Employees 11 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cellectar Biosciences, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-44.58 M-4.23as on Dec 31, 2024
-
EBITDA
$-51.49 M-32.8as on Dec 31, 2024
-
Latest Funding Round
$24.5 M (USD), Post-IPO
Sep 05, 2023
-
Investors
HHS
& 10 more
-
Employee Count
11
as on Dec 31, 2024
-
Acquired by
Novelos Therapeutics
(Apr 11, 2011)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cellectar Biosciences
Cellectar Biosciences is a publicly listed company on the NASDAQ with ticker symbol CLRB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of Cellectar Biosciences
- Total Funding Total Funding
- Total Rounds 12
- Last Round Post-IPO — $24.5M
-
First Round
First Round
(08 Jan 2008)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Post-IPO - Cellectar Biosciences | Valuation |
investors |
|
| Sep, 2022 | Amount | Grant - Cellectar Biosciences | Valuation |
investors |
|
| Sep, 2021 | Amount | Grant - Cellectar Biosciences | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cellectar Biosciences
Cellectar Biosciences has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, National Cancer Institute and Novelos Therapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia
|
Founded Year | Domain | Location | |
|
Private equity investment firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cellectar Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cellectar Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cellectar Biosciences Comparisons
Competitors of Cellectar Biosciences
Cellectar Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Lyra Therapeutics, TriSalus Life Sciences, Credence MedSystems and Foresee Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for ENT diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of drug delivery devices to treat cancers
|
|
| domain | founded_year | HQ Location |
Developer of smart devices for drug delivery
|
|
| domain | founded_year | HQ Location |
Injectables and NCEs for cancer and chronic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cellectar Biosciences
Frequently Asked Questions about Cellectar Biosciences
When was Cellectar Biosciences founded?
Cellectar Biosciences was founded in 2002 and raised its 1st funding round 6 years after it was founded.
Where is Cellectar Biosciences located?
Cellectar Biosciences is headquartered in Florham Park, United States. It is registered at Florham Park, New Jersey, United States.
How many employees does Cellectar Biosciences have?
As of Dec 31, 2024, the latest employee count at Cellectar Biosciences is 11.
What does Cellectar Biosciences do?
Founded in 2002 and based in Florham Park, United States, phospholipid drug conjugates are developed by the biotechnology firm for oncology applications. The lead product, CLR 131, incorporates iodine-131 to damage cancer cell DNA, while another variant targets solid tumors by arresting the cell cycle. Additional conjugates, such as CLR 1602-PTX for paclitaxel delivery, are pursued using a proprietary phospholipid ether platform that enables targeted drug transport to cancer cells.
Who are the top competitors of Cellectar Biosciences?
Cellectar Biosciences's top competitors include Insulet, Lyra Therapeutics and TriSalus Life Sciences.
Is Cellectar Biosciences publicly traded?
Yes, Cellectar Biosciences is publicly traded on NASDAQ under the ticker symbol CLRB.
Who are Cellectar Biosciences's investors?
Cellectar Biosciences has 11 investors. Key investors include HHS, National Cancer Institute, Novelos Therapeutics, Rosalind Advisors, and AIGH Capital Management.
What is Cellectar Biosciences's ticker symbol?
The ticker symbol of Cellectar Biosciences is CLRB on NASDAQ.